Synopsis
0
EU WC
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
Click Us!
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7658
Submission : 1988-09-06
Status :
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
About the Company : Transform your biologic formulations with Pfanstiehl, the industry leader in High-Purity Low Endotoxin Low Metals Parenteral grade excipient manufacturing. Our expertise spans isol...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;30...DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 16682
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 17512
DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5G...DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 17608
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML
USFDA APPLICATION NUMBER - 18883
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 18883
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML
USFDA APPLICATION NUMBER - 18883
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 18883
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML
USFDA APPLICATION NUMBER - 18883
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 18883
DOSAGE - INJECTABLE;INJECTION - 5MEQ/ML
USFDA APPLICATION NUMBER - 18947
DOSAGE - SOLUTION;IRRIGATION - 20MG/100ML;30M...DOSAGE - SOLUTION;IRRIGATION - 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 19416
DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5G...DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 19685
DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5G...DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 19685
DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5G...DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 19685
DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5G...DOSAGE - INJECTABLE;INJECTION - 20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML
USFDA APPLICATION NUMBER - 19685
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20163
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20163
DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20163
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.4MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20171
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.4MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20171
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.4MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20171
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20183
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20183
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20183
DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/10...DOSAGE - SOLUTION;INTRAPERITONEAL - 18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML
USFDA APPLICATION NUMBER - 20183
Related Excipient Companies
API Stability Enhancers
SPI Pharma has been solving formulation challenges using superior functional materials.
Dosage Form : Tablet
Grade : Oral
Application : API Stability Enhancers
Excipient Details : Effer-Soda is a surface modified sodium bicarbonate powder that eliminates formulation instability, expensive packaging & premature effervescence.
Parenteral
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
FDF DOSSIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EXCIPIENTS
Reply
25 Jul 2023
Reply
15 Oct 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
100
PharmaCompass offers a list of Sodium Lactate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Lactate manufacturer or Sodium Lactate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Lactate manufacturer or Sodium Lactate supplier.
PharmaCompass also assists you with knowing the Sodium Lactate API Price utilized in the formulation of products. Sodium Lactate API Price is not always fixed or binding as the Sodium Lactate Price is obtained through a variety of data sources. The Sodium Lactate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4, including repackagers and relabelers. The FDA regulates DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 supplier is an individual or a company that provides DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 active pharmaceutical ingredient (API) or DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 finished formulations upon request. The DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 suppliers may include DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 API manufacturers, exporters, distributors and traders.
click here to find a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 DMF (Drug Master File) is a document detailing the whole manufacturing process of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 active pharmaceutical ingredient (API) in detail. Different forms of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 DMFs exist exist since differing nations have different regulations, such as DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 DMF submitted to regulatory agencies in the US is known as a USDMF. DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 USDMF includes data on DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 Drug Master File in Japan (DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 JDMF) empowers DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 JDMF during the approval evaluation for pharmaceutical products. At the time of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 suppliers with JDMF on PharmaCompass.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP of the European Pharmacopoeia monograph is often referred to as a DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 Certificate of Suitability (COS). The purpose of a DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 to their clients by showing that a DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP has been issued for it. The manufacturer submits a DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP holder for the record. Additionally, the data presented in the DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 DMF.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 suppliers with NDC on PharmaCompass.
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 GMP manufacturer or DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 GMP API supplier for your needs.
A DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CoA (Certificate of Analysis) is a formal document that attests to DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4's compliance with DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 specifications and serves as a tool for batch-level quality control.
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CoA mostly includes findings from lab analyses of a specific batch. For each DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 may be tested according to a variety of international standards, such as European Pharmacopoeia (DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 EP), DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER-4 USP).
Comment (7)
